CRP and lymphopenia: No adverse events observed within 72 h of ExoFlo administration. A survival rate of 83% was observed. In total, 17 of 24 (71%) patients recovered, 3 of 24 (13%) patients remained critically ill though stable, and 4 of 24 (16%) patients expired for reasons unrelated to the treatment. Patients’ clinical status and oxygenation improved. Significant improvements in absolute neutrophil count and lymphopenia. Mean C-reactive protein, ferritin, and D-dimer reduction of 77%, 43% and 42%, respectively.